Skip to main content
Category

News Archive

etc-logo

Baltimore’s ETC (Emerging Technology Center) Announces Eighth Year of AccelerateBaltimore

By News Archive

etc-logo

ETC (Emerging Technology Center), Baltimore City’s award-winning technology and innovation center, announced today that its AccelerateBaltimore program will run for its eighth consecutive year, with funding from the Abell Foundation. Six companies will be competitively selected for the program, each receiving initial seed funding of $25,000 and $100,000 in follow-on funding will be awarded to one AccelerateBaltimore company judged to have the greatest potential for growth. ETC will accept applications from October 22 through December 10, 2018 at www.acceleratebaltimore.com.

Read More
iqvia-logo

Intersection between big data and therapeutic pipeline in neuromuscular disease will be life-changing for 250,000 patients and caregivers | Muscular Dystrophy Association

By News Archive

iqvia-logo

A new report funded by the Muscular Dystrophy Association (MDA) and released by the IQVIA Institute for Human Data Science indicates that genetic testing and breakthrough therapies will transform the diagnosis and care of neuromuscular disease within the next decade. The report, “Understanding Neuromuscular Disease Care,” highlights current gaps in care and opportunities to optimize care and accelerate the emergence of new therapies. Insights gained from a survey of health care professionals focused on the care of patients with neuromuscular disease are also included.

Read More
biopharma-laboratory-lab-pixa

Top 25 Biotech Companies of 2018

By News Archive

biopharma-laboratory-lab-pixa

While several biopharma giants (including Amgen, Novartis, and Merck & Co.) reported third-quarter earnings that beat expectations in recent days, biotechs appear to have been caught up in the past month’s stock market swoon. As of October 26, according to Zacks Equity Research, the stock prices of companies in its “medical-biomedical and genetics” sector, which includes smaller as well as larger biotechs, had fallen 10.3% over the previous six months, compared with a 1.6% increase for the overall S&P 500.

Read More
life-sciences-dna-pixa

2018’s Fiercest Women in Life Sciences – FiercePharma

By News Archive

life-sciences-dna-pixa

Things are looking up for women—or so they seem. In the era of #MeToo, more and more women are speaking up about workplace harassment and discrimination, and the perpetrators are increasingly held accountable. Industry groups, like the Biotechnology Innovation Organization (BIO), and states, such as California, are implementing rules to increase the proportion of women on corporate boards.

Read More
bhi-updated-logo-2017

Getting Paid for Your BioHealth Innovation – Reimbursement Planning (11/14)

By News Archive
  • bhi-updated-logo-2017How do you obtain coverage and payment for your technology?
  • Is the process different for medical devices from diagnostics or therapeutics?
  • Can digital apps be reimbursed?
  • How do I work with bundled payments?
  • What is the process for securing reimbursement codes?  Do I need different strategies based upon the point of care?
  • How much do I need to budget for a reimbursement strategy?  When do I need one?
  • How to I talk to investors about my reimbursement strategy? 

Learn the answers to these questions and more through the November 14th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 11/13 is required).

  • 8:15 a.m. Networking and Coffee
  • 8:30 a.m.  – Issues Overview (in person/by videoconference)
    • Speakers:  Brian Abraham, Founder, Lara Reimbursement Advisory
    • Luis Gutierrez, Entrepreneur-in-Residence, NHLBI and BioHealth Innovation
  • 9:30 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, TEDCO and Montgomery County. It is open to anyone in the BioHealth Capital Region.  

To register/For more information, email:  BHI@BioHealthInnovation.  (In person 1:1 scheduling:  www.tinyurl.com/BHIappointments.)

*Attendance at Overview in person/by videoconference required to participate in 1:1 sessions.

nih-logo

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to NIH SBIR Omnibus Solicitations

By News Archive

nih-logo

A ‘Direct-to-Phase II’ SBIR award is a Phase II award issued to a small business that did not receive a Phase I award for that research/research & development. Recent legislation has re-instated this SBIR Direct Phase II provision through Fiscal Year 2022 and NIH is re-implementing the SBIR Direct-to-Phase II program. The prior program had specific SBIR Direct-to-Phase II funding opportunity announcements (FOAs). These will not be needed now. The transition to FORMS-E allows NIH to track SBIR Direct-to-Phase II applications using a new check-box on the SBIR/STTR Information Form for Direct Phase II

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.